- Home
- RPAY vs PCRX Comparison
RPAY vs PCRX Comparison
Compare RPAY & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPAY
- PCRX
- Stock Information
- Founded
- RPAY 2006
- PCRX 2006
- Country
- RPAY United States
- PCRX United States
- Employees
- RPAY N/A
- PCRX N/A
- Industry
- RPAY Business Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- RPAY Consumer Discretionary
- PCRX Health Care
- Exchange
- RPAY Nasdaq
- PCRX Nasdaq
- Market Cap
- RPAY 688.3M
- PCRX 604.7M
- IPO Year
- RPAY N/A
- PCRX 2011
- Fundamental
- Price
- RPAY $7.85
- PCRX $16.52
- Analyst Decision
- RPAY Strong Buy
- PCRX Buy
- Analyst Count
- RPAY 7
- PCRX 10
- Target Price
- RPAY $12.29
- PCRX $26.60
- AVG Volume (30 Days)
- RPAY 669.5K
- PCRX 545.3K
- Earning Date
- RPAY 11-12-2024
- PCRX 11-06-2024
- Dividend Yield
- RPAY N/A
- PCRX N/A
- EPS Growth
- RPAY N/A
- PCRX N/A
- EPS
- RPAY N/A
- PCRX N/A
- Revenue
- RPAY $310,758,000.00
- PCRX $694,957,000.00
- Revenue This Year
- RPAY $9.21
- PCRX $4.59
- Revenue Next Year
- RPAY $7.86
- PCRX N/A
- P/E Ratio
- RPAY N/A
- PCRX N/A
- Revenue Growth
- RPAY 5.95
- PCRX 4.40
- 52 Week Low
- RPAY $7.04
- PCRX $11.16
- 52 Week High
- RPAY $11.27
- PCRX $35.95
- Technical
- Relative Strength Index (RSI)
- RPAY 46.13
- PCRX 44.28
- Support Level
- RPAY $7.82
- PCRX $16.11
- Resistance Level
- RPAY $9.75
- PCRX $18.34
- Average True Range (ATR)
- RPAY 0.40
- PCRX 0.83
- MACD
- RPAY 0.00
- PCRX -0.17
- Stochastic Oscillator
- RPAY 21.85
- PCRX 5.33
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segment, Consumer Payment and Business Payments.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.